After getting its hands on a massive Quebecois manufacturing plant from Sandoz in 2022, French CDMO Delpharm is making good ...

Wondering if you should look beyond American markets to build your fortune? This widely held international fund offers a few ...

Most major stock indexes across the globe ended higher on a weekly basis. Investors assessed key economic data, mixed corporate results, potential progress towards a ceasefire in Ukraine along with ...

Novo Nordisk’s bid to provide a once-weekly basal ... but comes after insulin icodec has already been approved in the EU, Canada, Australia, Japan, and Switzerland under the Awiqli brand name ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that market experts are talking about these days. Piper Sandler’s Chief Market ...

Novo Nordisk received a boost from a bullish analyst note. The company also continues to be the pacesetter in the limited market for weight-loss drugs. That gravity-defying boost was due in no ...

UBS's Jo Walton reiterated the Swiss bank's buy recommendation on Novo Nordisk stock at a price target of 750 Danish kroner ($110) per share. It wasn't immediately apparent why the analyst ...

COPENHAGEN (Reuters) - Novo Nordisk (NYSE:NVO) has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NYSE:NVO) said on Friday ...

Novo Nordisk A/S has a twelve month low of $73.80 and a twelve month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.